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The value of abnormal blood lipids and apo-lipoprotein levels 
to predict ischaemic heart disease (IHD) has been studied 
for decades, with the initial focus shifting from studying the 
relationship with total blood cholesterol (TC) to that of the 
individual components associated with TC. TC is a composite 
measure of the cholesterol content of lipoprotein particles such 
as low-density lipoprotein cholesterol (LDLC) and high-density 
lipoprotein cholesterol (HDLC). The dyslipidaemic patterns 
of high levels of LDLC and/or low HDLC have been found 
to impart high risk for developing IHD, and justify aggressive 
treatment to reduce the risk.1 Recent data suggest that levels of 
the actual apo-lipoproteins such as ApoB and ApoA1 are the 
most powerful lipid predictors for IHD.2  
In most developing countries the only lipid-related 
population-based data available are TC levels. However, 
TC data can be used effectively as a proxy measure of other 
dyslipidaemic markers of risks for IHD, ischaemic stroke 
and other vascular diseases. The risks of TC are continuous 
and occur even in populations with TC levels much lower 
than those experienced in North American and European 
populations.3,4 The level of TC usually increases with age in 
populations with a westernised lifestyle. High TC levels are 
associated with a diet high in fat (particularly saturated animal 
fat), with cholesterol in the diet, and with lack of fibre.
Cardiovascular disease (CVD) risk factors, including high 
TC, are already prevalent in the South African population, 
and are set to increase with growing urbanisation of the black 
African population.5-7 (Population group classification is used 
in this article to demonstrate differences in risk-factor profile 
and the subsequent burden. Data are based on self-reported 
categories according to the population group categories 
used by Statistics South Africa. Mentioning such differences 
allows for a more accurate estimate of the overall burden 
and may assist in higher effectiveness of future interventions. 
The authors do not subscribe to this classification for any 
other purpose.) In the black African population currently 
the predominant CVD is cerebrovascular disease (stroke).8 
However, as the TC levels increase, the CVD pattern will 
shift towards higher rates of IHD. It is already consistently 
reported that the caseload of IHD is on the increase in the black 
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Objectives. To estimate the burden of disease attributable to high 
cholesterol in adults aged 30 years and older in South Africa in 
2000.
Design. World Health Organization comparative risk assessment 
(CRA) methodology was followed. Small community studies 
were used to derive the prevalence by population group. 
Population-attributable fractions were calculated and applied 
to revised burden of disease estimates for the relevant disease 
categories for each population group. The total attributable 
burden for South Africa in 2000 was obtained by adding the 
burden attributed to high cholesterol for the four population 
groups. Monte Carlo simulation-modelling techniques were 
used for uncertainty analysis.
Setting. South Africa.
Subjects. Black African, coloured, white and Indian adults aged 
30 years and older.
Outcome measures. Mortality and disability-adjusted life years 
(DALYs) from ischaemic heart disease (IHD) and ischaemic 
stroke.
Results. Overall, about 59% of IHD and 29% of ischaemic stroke 
burden in adult males and females (30+ years) were attributable 
to high cholesterol (≥ 3.8 mmol/l), with marked variation by 
population group. High cholesterol was estimated to have 
caused 24 144 deaths (95% uncertainty interval 22 404 - 25 286) or 
4.6% (95% uncertainty interval 4.3 - 4.9%) of all deaths in South 
Africa in 2000. Since most cholesterol-related cardiovascular 
disease events occurred in middle or old age, the loss of life 
years comprised a smaller proportion of the total: 222 923 
DALYs (95% uncertainty interval 206 712 - 233 460) or 1.4% of 
all DALYs (95% uncertainty interval 1.3 - 1.4%) in South Africa 
in 2000.
Conclusions.  High cholesterol is an important cardiovascular 
risk factor in all population groups in South Africa. 
S Afr Med J 2007; 97: 708-715.
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African population, particularly in urban hospitals. It has been 
suggested that the incidence of IHD in the urban black African 
population may even be as high as in the white population.9
Nine community studies10-19 have been conducted in South 
Africa, but there are no nationally representative data on TC 
levels. This article aimed to use the community study data 
to derive estimates of national prevalence of exposure to 
high TC in adults aged 30 years and older by sex, age and 
population group. It also aimed to quantify the adverse health 
consequences associated with high TC by population group, 
and to estimate the burden of disease attributed to high TC 
by sex, population and age group in South Africa for the year 
2000.
Methods
Using World Health Organization (WHO) comparative 
risk assessment (CRA) methodology3,20 the disease burden 
attributable to a particular risk factor is estimated by 
comparing current local health status with a theoretical 
minimum counterfactual with the lowest possible risk. The 
attributable fraction of disease burden in a population is 
determined by prevalence of exposure to the risk factor in the 
population and the relative risk (RR) of disease occurrence 
given exposure. Cholesterol was defined as a continuous 
variable with mean and standard deviation (SD) values of total 
serum cholesterol expressed in millimoles per litre of serum 
(mmol/l). 
The outcomes assessed were IHD and ischaemic stroke. IHD 
was chosen in the WHO CRA study4 on the basis of clear and 
consistent positive associations observed in cohort studies, 
as well as on the evidence of reversibility in clinical trials 
of treatments to lower cholesterol levels. There is a positive 
association between cholesterol and ischaemic stroke, but 
there is a qualitatively different association with haemorrhagic 
stroke.4 As the endpoints had to be mapped to the South 
African burden of disease study classification system, total 
stroke (which includes both stroke subtypes) was used in this 
analysis. It was necessary, however, to adjust stroke burden 
by the proportions of total fatal and non-fatal stroke that were 
ischaemic stroke, using the proportions by stroke subtype for 
the WHO African subregion AFR-E, which includes South 
Africa.4 Although cholesterol has been shown to be inversely 
associated with cancer and chronic respiratory disease, 
evidence suggests that these associations were rather due to 
the effects of the diseases on cholesterol levels, and hence these 
outcomes were not included in the analysis.4
Estimates of mean TC levels and SDs by age and sex for 
adults aged 30 years and older were obtained by pooling 
data from the nine available studies10-19 of randomly selected 
subjects conducted between 1980 and 2000. The means and SDs 
were weighted according to the number of observations of each 
study and the SD also took into account the difference between 
the means of the studies. The pooled TC mean was calculated 
as m=Σωimi and the pooled SD as
where ωi was a proportional weight based on the number of 
subjects in each study and mi and sdi were the study mean and 
SD respectively.  
Owing to differences in prevalence of CVD in the four 
population groups, the analysis was carried out separately for 
each. Age- and sex-related population group-specific mean 
cholesterol levels from these community studies were weighted 
according to the size of the population in each age-sex group in 
South Africa in 2000.21 
Cholesterol values for those aged 70 - 79 years and > 80 years 
were assumed to be the same as for the 60 - 69-year age group, 
owing to the extremely limited availability of cholesterol 
levels in community studies for adults older than 65. This may 
have led to a slight overestimate in the white population, as 
the association between age and cholesterol is non-linear.4 In 
high-cholesterol regions, cholesterol levels for females increase 
between the ages of 30 and 65 years, and then fall slightly. In 
males, levels increase between the ages of 30 and 50 years, and 
then flatten before declining slightly in older age.4 Lawes et al.4 
did not assume a decline in older ages in the low-cholesterol 
AFR-E region.
A comprehensive review of the literature by Lawes et 
al.4 identified the Asia-Pacific Cohort Studies Collaboration 
analysis of 1999 (APCSC 1999)22 as the primary data source 
for RR estimates of IHD and ischaemic stroke. APCSC 1999 
analyses offered greater sample size, and while other available 
meta-analyses used tabular data, APCSC analyses were based 
on individual participant data and provided age-specific 
analyses of total stroke and stroke subtypes. These analyses 
could therefore more reliably adjust for confounding and 
provide more reliable estimates of hazard ratios.4 
In this analysis we used risk ratios based on more recent 
analyses of the APCSC data, which reflect a smoother 
estimate of the attenuation of RRs across age, as shown in 
Table I (S Vander Hoorn, University of Auckland – personal 
communication, 2005). These same risk ratios were used across 
population groups. Related health outcomes and ICD-1023 
codes are also presented in Table I.
Similar to the case of blood pressure, regression dilution 
bias must be taken into account when observational data 
are used to estimate the association between cholesterol and 
cardiovascular endpoints. This bias occurs as baseline or 
‘one-off’ measures of TC are subject to random fluctuations, 
due partly to the measurement process and partly to real but 
temporary deviations at a single time-point from the ‘usual’ 
exposure level. The measured values have a wider distribution 
than the ‘usual’ values, and with repeated measures result in 
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‘regression to the mean’ of values, whereby an initially extreme 
observation tends to become less abnormal with replication. 
Since this bias is accounted for in the estimates of RR, it also 
needs to be reflected in a narrower distribution around the 
estimated mean TC levels.24,25 A correction for regression 
dilution resulting from the ‘time-dependent’ variation from 
the usual level is made by multiplying the SDs across all age-
sex categories by a factor of 0.625 (S Vander Hoorn – personal 
communication).  
Customised MS Excel spreadsheets based on templates 
used in the Clinical Trial Research Unit at the University of 
Auckland (S Vander Hoorn – personal communication, 2005) 
as well as Australian studies (T Vos, University of Queensland 
– personal communication, 2005) were used to calculate the 
attributable burden using a discrete version of the general 
potential impact fraction (see below), taking into account 
continuous risk factor disease exposures compared with 
a theoretical minimum distribution (conferring the lowest 
possible risk), on a categorical scale. 
where n = the number of exposure categories; Pi = the 
proportion of the population in exposure category i; RRi = 
the RR for exposure category i; and P’i = the proportion of 
the population in exposure category i in the counterfactual 
distribution.
The theoretical minimum exposure distribution is zero in 
most cases, since zero exposure reflects minimum risk (e.g. 
no smoking). For TC, however, zero exposure would be 
physiologically impossible, and therefore is an inappropriate 
choice as the theoretical minimum. Lawes et al.4 examined data 
from ‘unacculturated’ populations which included hunter-
gatherer societies where mean values were as low as 3.0 - 3.5 
mmol/l. With diets low in salt and animal fat, the prevalence 
of CVD is very low in these ‘low-cholesterol’ populations. In 
populations such as China, data suggest that the relationship 
between cholesterol and cardiovascular endpoints may 
continue, without a threshold, below cholesterol levels of about 
4.0 mmol/l. Based on this evidence, the theoretical minimum 
of usual cholesterol was set at a mean of 3.8 mmol/l (SD 0.6 
mmol/l – ‘usual’), for all age, sex and population groups.4 
PAFs were then applied to revised South African burden of 
disease estimates for 2000 for each population group,21 deaths, 
premature mortality or years of life lost (YLL), years lived with 
disability (YLD), and disability-adjusted life years (DALYs) for 
the relevant disease categories, to calculate attributable burden. 
The total attributable burden for South Africa in 2000 was 
obtained by adding the burden attributed to high cholesterol 
for the four population groups. 
Monte Carlo simulation-modelling techniques were used 
to present uncertainty ranges around point estimates that 
reflect all the main sources of uncertainty in the calculations. 
We used the @RISK software version 4.5 for Excel,26 which 
allows multiple recalculations of a spreadsheet, each time 
choosing a value from distributions defined for input variables. 
Normal probability distributions were specified around the 
mean TC levels by age, sex and population group. For the RR 
input variables a normal distribution was specified, with the 
natural logarithm of the RR estimates as the entered means 
of the distribution and the standard errors of these estimates.  
For each of the output variables (namely attributable burden 
as a percentage of total burden in South Africa, 2000), 95% 
uncertainty intervals were calculated bounded by the 2.5th and 
97.5th percentiles of the 2000 iteration values generated.
Results 
Table II shows the estimated mean TC levels, which were 
highest in the white population group, followed closely by 
the coloured and Indian groups. The black African population 
had the lowest mean levels for males and females at all ages, 
with levels in urban areas only slightly (but not significantly) 
higher than rural levels. Mean TC levels in women were higher 
than in men above 45 years of age in all population groups. In 
the youngest age group, however, levels in men were higher 
than in women in the Indian, coloured and white population 
groups. TC levels in white women increased between the 
ages of 30 and 65 years, and were then assumed to remain flat 
– although they should fall slightly afterwards. In white males, 
levels increased between the ages of 30 and 50 years and then 
flattened, although they are also supposed to decline slightly 
in older age groups. Similar age patterns were observed in 
Indian and coloured males and females, but not in the black 
African population. In the black African population the 
increases between the 30 - 44-year and 45 - 59-year age groups 
were not as marked as in the other population groups, and in 
black African men the levels appeared to continue increasing 
between ages of 30 and 65 years.
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Table I. Age-specific hazard ratios (95% CI) for 1 mmol/l difference in usual total cholesterol 
Related health outcome (ICD-10)23        30 - 44 yrs     45 - 59 yrs     60 - 69 yrs     70 - 79 yrs        80+ yrs
Ischaemic heart disease (I20-I25) 0.27 (0.20 - 0.38) 0.48 (0.44 - 0.52) 0.64 (0.62 - 0.67) 0.70 (0.66 - 0.75) 0.70 (0.67 - 0.73)
Ischaemic stroke (I63) 0.61 (0.32 - 1.18) 0.69 (0.59 - 0.80) 0.76 (0.64 - 0.90) 0.82 (0.68 - 0.99) 0.90 (0.75 - 1.08)
 
Source: S Vander Hoorn, University of Auckland – personal communication, 2005; more recent reanalysis of Asia-Pacific Cohort Studies Collaboration (APCSC)22 data. 
95% CI =  95% confidence interval.
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Table II. Estimates of age-specific mean total cholesterol levels and standard deviations (SDs) (mmol/l) for males and females 
by population group, South Africa, 2000
          Age groups (yrs)                       Data sources
Population  Sex Parameter 30 - 44 45 - 59 60 - 69 70 - 79 80+ Study site                                   Year    N
Urban black African*  Males Mean    4.4    4.5    4.7    4.7 4.7 Cape Town (Western Cape)12     1990   665 
  SD†    0.8    0.7    0.7    0.7 0.7 Mangaung (Free State)10‡           1990/1   758
 Females Mean    4.5    5.0    5.1    5.1 5.1 Durban (KwaZulu-Natal)13       1986   232
  SD†    0.6    0.7    0.6    0.6 0.6
Rural black African* Males Mean    4.4    4.6    4.6    4.6 4.6 QwaQwa (Free State)10‡             1990/1   853
  SD†    0.7    0.6    0.7    0.7 0.7 Dikgale (Limpopo)11§                 1997/8   1 494
 Females Mean    4.4    4.7    5.0    5.0 5.0
  SD†    0.6    0.7    0.7    0.7 0.7
Black African  Males Mean    4.4    4.5    4.7    4.7 4.7 Weighted estimate
  SD†    0.7    0.7    0.7    0.7 0.7
 Females Mean    4.4    4.9    5.1    5.1 5.1
  SD†    0.6    0.7    0.7    0.7 0.7
Coloured Males Mean    5.7    5.8    5.6    5.6 5.6 Cape Town (Western Cape)14      1982   779
  SD†    0.8    0.8    0.7    0.7 0.7 Mamre (Western Cape)15            1996   646
 Females Mean    5.3    6.2    6.4    6.4 6.4
  SD†    0.7    0.8    0.7    0.7 0.7
White Males Mean    5.8    6.3    6.2    6.2 6.2 Durban (KwaZulu-Natal)17‡       1987   354
  SD†    0.9    0.8    0.7    0.7 0.7 Robertson, Swellendam,            1983        2 722 
 Females Mean    5.5    6.4    7.2    7.2 7.2 Riversdal (Western Cape)18¶ 
  SD†    0.7    0.8    0.9    0.9 0.9 Riversdal, Caledon, Bredasdorp  1993   327 
        (Western Cape)19II
Asian/Indian Males Mean    5.8    6.1    5.6    5.6 5.6 Durban (KwaZulu-Natal)16‡       1984/6   601
  SD†    0.8    0.8    0.7    0.7 0.7
 Females Mean    5.3    5.9    6.1    6.1 6.1
  SD†    0.7    0.8    0.8    0.8 0.8
South Africa* Males Mean    4.8    5.0    5.2    5.2 5.2 Weighted estimate
  SD†    0.8    0.9    0.8    0.8 0.8
 Females Mean    4.6    5.3    5.7    5.7 5.7
  SD†    0.7    0.9    0.9    0.9 0.9
*Rural black African, urban black African and South African average estimates are presented but were not used in the calculations. 
†Corrected for regression dilution resulting from time-dependent change in ‘usual’ level (ratio = 0.625). 
‡Oldest age category in study is 55 - 69 years. 
§Data of Dikgale study extracted from data from reference 11, youngest age group, 30 - 34 years. 
¶Data for men of the CORIS study extracted from data from reference 18. 
IIAge group 35 - 44 years. 
Table III. Prevalence with serum cholesterol values above 5 mmol/l* by population group, age and sex, South Africa, 2000
  Proportion (%) with serum cholesterol ≥ 5 mmol/l
Population group Age group (yrs) Males Females Persons
Black African 30 - 44   21.5     17.4    19.4
 45 - 59  24.5     43.5    34.5
 60+  32.2     54.1    44.9
 30+  23.8     30.9    27.6
Coloured 30 - 44  80.8     66.9    73.6
 45 - 59  84.5     94.8    90.0
 60+  79.6     97.9    90.4
 30+  81.7     79.9    80.7
White  30 - 44  83.9     75.0    79.5
 45 - 59  93.8     95.3    94.6
 60+  96.0     99.4    97.9
 30+  90.0     88.4    89.2
Asian/Indian 30 - 44  84.9     65.1    74.9
 45 - 59  92.3     87.8    89.9
 60+  78.4     90.3    85.2
 30+  86.5     77.4    81.7
South Africa 30 - 44  38.9     30.3    34.4
 45 - 59  50.5     63.2    57.4
 60+  58.0     78.7    70.7
 30+  45.2     49.6    47.6
*Current clinical cut-off for hypercholesterolaemia.
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The estimated prevalence of hypercholesterolaemia (TC ≥ 
5 mmol/l, the current clinical cut-off) by population group 
in the age groups 30 years and older is shown in Table III. 
The differences between the prevalence rates in the black 
African population and the other three groups are striking, 
and are consistent with the lower levels of urbanisation and 
concomitant incomplete adoption of Western lifestyles in this 
group. 
The PAFs for high cholesterol for males, females and adults 
of 30+ years are shown in Table IV. Attributable fractions were 
higher in females for all related outcomes and in all population 
groups. Overall, about 59% of IHD and 29% of ischaemic 
stroke burden in adult males and females (30+ years of age) 
were attributable to high cholesterol (≥ 3.8 mmol/l). 
High cholesterol was estimated to cause 24 144 deaths (95% 
uncertainty interval 22 404 - 25 286) or 4.6% (95% uncertainty 
interval 4.3 - 4.9%) of all deaths in South Africa in 2000.  
There are more female than male attributable deaths, with 
attributable deaths from ischaemic stroke in females double 
those in males (Table IV). Since most cholesterol-related CVD 
events occurred in middle or old age, the loss of life years 
comprises a smaller proportion of the total: 222 923 DALYs 
(95% uncertainty interval 206 712 - 233 460) or 1.4% of all 
DALYs (95% uncertainty interval 1.3 - 1.4%) in South Africa in 
2000.
Age-standardised attributable mortality rates by population 
group are presented in Fig. 1. Large population group 
differences were observed, with the highest rates seen in 
Indian males and females, followed by white males and 
females. Coloured adults had intermediate rates, with very 
low rates observed in the black African population group. It 
is interesting to note that in the Indian and white groups, age-
standardised cholesterol-attributable mortality rates in males 
were higher than in females. However, in the black African and 
coloured groups the rates in females were slightly higher than 
in males.
The contribution of IHD and ischaemic stroke to total 
attributable burden by population group is shown in Fig. 
2. While ischaemic stroke and IHD accounted for similar 
proportions of total burden in the black African population 
group, IHD accounted for the majority of the burden in 
the Indian and white population groups, with a very small 
contribution from ischaemic stroke.
Discussion
Overall, the results suggest that a considerable proportion 
of CVD in South Africa can be attributed to non-optimal 
cholesterol levels, which translates into a high proportion of 
deaths and disability. Worldwide, 56% of IHD mortality and 
disease burden was attributable to cholesterol levels of more 
than 3.8 mmol/l, which translated to 3.6 million deaths in the 
year 2000.4 In South Africa, 59% of IHD was attributable to 
raised cholesterol. In addition, 29% of ischaemic stroke was 
attributable to raised cholesterol, which compares with the 
worldwide estimate of 32% (range 25 - 45% by subregion).4 
Overall, 4.4 million deaths (about 7.9% of the total) and 40.4 
million DALYs (2.8% of the total) worldwide were estimated 
to be due to non-optimal cholesterol levels. About 40% of the 
cholesterol-related attributable burden occurred in developed 
subregions, 20% in low-mortality developing sub-regions, and 
a further 40% in high-mortality developing subregions. The 
relative impact of attributable deaths and DALYs was highest 
in the European subregions, with the highest mean cholesterol 
levels.4
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Fig. 1. Age-standardised cholesterol-attributable mortality rates by  
population group and sex, South Africa, 2000.
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Fig. 2. Burden attributable to high cholesterol by population group,  
South Africa, 2000.
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In South Africa, although the national 
IHD PAFs (59%) were similar to the global 
average, there were marked population group 
differences, ranging from 42% of IHD in the 
black African population to 73% in the white 
population. Similarly, PAFs for ischaemic 
stroke were as low as 26% of disease burden 
in the black African population and as high as 
48% in the white population, giving an overall 
average of 29%, which is similar to the global 
average. 
The attributable mortality by population 
group spanned the full spectrum observed 
globally. Cholesterol-attributable mortality 
was highest in the Indian population, where it 
accounted for 22.2% (95% uncertainty interval 
20.7 - 23.3%) of all deaths, followed by the 
white population, where it accounted for 
20.5% (95% uncertainty interval 18.5 - 21.8%) 
of all deaths in 2000. Attributable mortality 
was lowest in the black African group, 
accounting for only 1.8% (95% uncertainty 
interval 1.5 - 2.0%) of all deaths. In the 
coloured population, 8.8% (95% uncertainty 
interval 7.9 - 9.5%) of all deaths in 2000 could 
be attributed to non-optimal cholesterol 
levels.
The TC values (Table II) in the black African 
population group were generally lower than 
the levels found in the other three population 
groups, with differences being larger in 
older participants than in younger ones. This 
may suggest that the younger black African 
participants have already adopted a more 
westernised diet and lifestyle. The ratio of 
HDLC to TC has generally been found to be 
higher in the studies conducted in the black 
African population group10,12 than in the other 
three groups. This suggests that the black 
African population group with its lower TC 
levels is experiencing additional protection 
against atherosclerosis-related diseases by 
virtue of its relatively higher proportion of 
protective HDLC.27 The implication of this is 
that the real estimated impact of high TC in 
the black African population might have been 
overestimated in the data presented. 
Only six of the studies reported on the 
LDLC levels in the black African and coloured 
populations.10-15 As would be expected, LDLC 
levels in the black African population group 
were significantly lower than in the coloured 
group, again pointing to the relatively lower 
level of risk in the black African group 
compared with others.27  
Traditionally in the black African 
population TC levels were found to be 
low.11,12 It is therefore an unexpected 
finding that about 3.5 million (28% of 
all) black African people 30 years and 
older were above the clinical cut-off for 
hypercholesterolaemia (TC level 5 mmol/l 
or higher), a prevalence rate similar to 
that for hypertension in this ethnic group. 
This suggests that health services should 
consider screening for high cholesterol 
in black African people aged 30 years 
or older with other cardiovascular risk 
factors. Furthermore, older women were 
found to have hypercholesterolaemia 
far more frequently than older men; this 
may be associated with the high obesity 
rates recorded in older black African 
women. In the other population groups 
hypercholesterolaemia in men occurred 
at least as frequently as in women, with 
younger women having lower prevalence 
rates than men and older women 
having much higher rates than men. By 
extrapolating the prevalence to all South 
Africans aged 30 years or older, these 
findings indicate that almost 8 million 
people carry a risk for a chronic disease 
of lifestyle by virtue of their total serum 
cholesterol level using the clinical cut-
off of 5 mmol/l. However, it needs to be 
remembered that for the black African 
population the TC values represent a higher 
proportion of protective HDLC levels than 
in the other groups.
Interventions should follow a two-
pronged approach: population-wide 
interventions aimed at lowering cholesterol 
levels and other cardiovascular risk factors 
among the whole population, and effective 
clinical management for individuals who 
are at high absolute risk for CVD. 
High blood cholesterol can be treated 
effectively by lifestyle modification of diet 
and physical activity, combined with the use 
of medication if the lifestyle modification 
does not result in achieving normal blood 
cholesterol levels.1 The lifestyle approach 
includes a diet with reduced intake of all 
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fats, and replacement of saturated fats and trans-fatty acids 
with mono- and polyunsaturated fats. An increase of soluble 
fibre from unrefined cereals, fruits and vegetables also reduces 
blood cholesterol, as do plant sterols and stanols which are 
now added to some margarines.28 Body mass should be 
reduced to normal levels along with maintaining a regular 
pattern of aerobic physical activity.1 Cholesterol-lowering 
medication has been shown to save lives.29 
Regardless of treatment choice, guidelines defining eligibility 
for medication use must focus on absolute or global clinical 
risk, in which high cholesterol is one of many CVD risk factors 
assessed, instead of individual risk factor approaches. There 
has been a shift away from considering the management of 
individual risk factors based on a single threshold. The review 
by Jackson et al.30 shows that providing people at high absolute 
risk for CVD with blood pressure and cholesterol-lowering 
medications is a more effective approach than considering 
single risk factor thresholds in isolation. They argue that 
clinical management guidelines for the separate risk factors be 
replaced by an integrated management guideline for CVD. 
In their review of cost-effective interventions for developing 
countries, Rogers et al.31 conclude that providing people at 
high absolute risk for CVD with generic blood pressure and 
cholesterol-lowering agents is cost-effective. However, there 
remains an extensive research agenda for the development, 
implementation and evaluation of such a strategy. They argue 
that there must be parallel efforts to reduce the underlying 
risks for CVD. However, as the cost-effectiveness of 
population-wide initiatives is very sensitive to variations in the 
risk for CVD and the nature of the intervention, there is a need 
for further research.31 
The experience internationally with highly active anti-
retroviral treatment (HAART) has shown that these drugs 
may result in a metabolic syndrome qualitatively similar to 
that seen in obesity-related diabetes (diabesity).32-34 These 
patients develop insulin resistance which is frequently severe 
enough to cause lipodystrophy,35 which in turn is manifested 
by a central distribution of adiposity, but at other times by 
lipo-atrophy – an apparent paradox also seen in other causes 
of insulin resistance. The dyslipidaemia also manifests as a 
high-triglyceride/low-HDLC syndrome, and severe cases 
can present as a chylomicronaemia syndrome,33 and is 
associated with an increased cardiovascular risk,36 mediated by 
mechanisms very similar to those postulated in diabesity. 
South Africa is in the middle of an HIV epidemic which is 
predicted to increase, and as HAART has now become more 
readily available, we can expect an increase in this peculiar 
insulin resistance syndrome and the associated increased risk 
for IHD in patients with AIDS on antiretroviral treatment.
A limitation of this study is that it is not based on TC data 
from recent national representative surveys, but estimated 
from a number of smaller surveys conducted in localised areas. 
Some of these were conducted more than 2 decades ago, and 
may not reflect current TC levels in these populations since 
national awareness campaigns have influenced lifestyle and 
diet, particularly in the white population.19 
Conclusions 
High TC is found in more South Africans than anticipated, 
and is an important cardiovascular risk factor in all population 
groups in South Africa. The data also suggest that TC levels 
are increasing in the black African population, particularly 
in the younger and more urbanised sector. This trend will 
continue unless the necessary population-based interventions 
are initiated. This will require promotion of a prudent diet for 
all South Africans by the National Department of Health, the 
Heart and Stroke Foundation of South Africa and the food 
industry. 
The AIDS epidemic and the treatment of large numbers of 
patients on antiretroviral agents will also affect the pattern 
of dyslipidaemia in the country; the use of HAART results in 
insulin resistance, diabesity and abnormal lipid profiles.
To accurately assess the lipid-related risk for IHD in black 
African people, it is necessary to avoid TC measurement and to 
focus on measuring LDLC levels or ApoB lipoprotein levels if 
cost-effective ways of identifying people at risk for IHD are to 
be found.
The data presented here emphasise that dyslipidaemia in South 
Africa is mostly an unrecognised – and consequently undiagnosed 
and poorly treated – condition. This will have to be addressed if 
IHD and stroke rates are to be contained in the country.
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